NEONC Technologies Secures $2M in Fourth Private Placement at Premium to Market Price
NTHI sits 49% above its 52-week low of $3.2 on elevated volume (2.8× avg).
Summary
NEONC Technologies Holdings, Inc. announced a $2 million private placement, issuing shares and warrants at prices significantly above its current stock price, to fund its NEO216 preclinical trials.
Key Events · Financing and Capital Events · NTHI
-
Secured $2 Million in Private Placement
The company completed an initial closing under a fourth Securities Purchase Agreement, raising approximately $2 million.
-
Premium Pricing Achieved
Shares were issued at $7.20, a significant premium compared to the current stock price of $4.78, with five-year warrants exercisable at $9.00.
-
Funding Preclinical Trials
Proceeds from this financing will be used to fund the NEO216 preclinical trials, advancing the company's pipeline.
-
Part of Larger Capital Raise Effort
This is the fourth in a series of private placements, contributing to a total of approximately $14.1 million raised to address liquidity needs and support operations.
Analysis · NTHI · Life Sciences
This 8-K details the fourth Securities Purchase Agreement, securing an additional $2 million for NEONC Technologies. This capital raise is particularly significant given the company's previously disclosed "going concern" warning, indicating a critical need for liquidity. The shares were sold at $7.20, a substantial premium to the current market price of $4.78, and warrants were issued with an exercise price of $9.00. This premium pricing suggests strong investor confidence or strategic interest, which is a positive signal for the company's valuation and future prospects. The proceeds are earmarked for funding NEO216 preclinical trials, directly supporting the company's core R&D efforts in the life sciences sector. This latest funding round contributes to the approximately $14.1 million raised through four private placements, as recently reported, providing crucial runway for operations and clinical development.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTHI was trading at $4.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119.1M. The 52-week trading range was $3.20 to $12.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.